ADCT
Price:
$1.99
Market Cap:
$192.41M
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relap...[Read more]
Industry
Biotechnology
IPO Date
2020-05-18
Stock Exchange
NYSE
Ticker
ADCT
According to ADC Therapeutics SA’s latest financial reports and current stock price. The company's current ROE is 131.30%. This represents a change of 290.04% compared to the average of 33.66% of the last 4 quarters.
The mean historical ROE of ADC Therapeutics SA over the last ten years is -57.99%. The current 131.30% ROE has changed -326.41% with respect to the historical average. Over the past ten years (40 quarters), ADCT's ROE was at its highest in in the June 2023 quarter at 548.57%. The ROE was at its lowest in in the March 2023 quarter at -157.69%.
Average
-57.99%
Median
-85.46%
Minimum
-175.59%
Maximum
161.93%
Discovering the peaks and valleys of ADC Therapeutics SA ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 170.36%
Maximum Annual ROE = 161.93%
Minimum Annual Increase = -Infinity%
Minimum Annual ROE = -175.59%
Year | ROE | Change |
---|---|---|
2023 | 161.93% | -192.22% |
2022 | -175.59% | 26.79% |
2021 | -138.50% | 88.66% |
2020 | -73.41% | -29.95% |
2019 | -104.79% | 7.47% |
2018 | -97.51% | 170.36% |
2017 | -36.07% | -Infinity% |
The current ROE of ADC Therapeutics SA (ADCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-50.72%
5-year avg
-66.07%
10-year avg
-57.99%
ADC Therapeutics SA’s ROE is greater than Passage Bio, Inc. (-72.53%), greater than Black Diamond Therapeutics, Inc. (-68.08%), greater than TCR2 Therapeutics Inc. (-71.90%), greater than Harpoon Therapeutics, Inc. (-19.66%), greater than Alector, Inc. (-108.77%), greater than Century Therapeutics, Inc. (-66.58%), greater than Homology Medicines, Inc. (-100.91%), greater than Generation Bio Co. (-104.85%), greater than Stoke Therapeutics, Inc. (-54.45%), greater than Ultragenyx Pharmaceutical Inc. (-187.12%), greater than Crinetics Pharmaceuticals, Inc. (-36.12%), greater than Arvinas, Inc. (-50.26%), greater than Revolution Medicines, Inc. (-33.67%), greater than Kura Oncology, Inc. (-44.09%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Avidity Biosciences, Inc. (-27.66%), less than Protagonist Therapeutics, Inc. (34.68%), greater than Design Therapeutics, Inc. (-18.01%), greater than ALX Oncology Holdings Inc. (-93.02%), greater than Aadi Bioscience, Inc. (-71.87%), greater than AlloVir, Inc. (-78.95%),
Company | ROE | Market cap |
---|---|---|
-72.53% | $40.03M | |
-68.08% | $123.92M | |
-71.90% | $58.11M | |
-19.66% | $865.08M | |
-108.77% | $188.03M | |
-66.58% | $86.73M | |
-100.91% | $3.02M | |
-104.85% | $73.47M | |
-54.45% | $614.95M | |
-187.12% | $4.05B | |
-36.12% | $5.00B | |
-50.26% | $1.24B | |
-33.67% | $8.01B | |
-44.09% | $695.21M | |
-32.52% | $1.98B | |
-27.66% | $3.77B | |
34.68% | $2.42B | |
-18.01% | $351.62M | |
-93.02% | $98.63M | |
-71.87% | $70.49M | |
-78.95% | $52.01M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ADC Therapeutics SA using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ADC Therapeutics SA or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is ADC Therapeutics SA's ROE?
How is the ROE calculated for ADC Therapeutics SA (ADCT)?
What is the highest ROE for ADC Therapeutics SA (ADCT)?
What is the 3-year average ROE for ADC Therapeutics SA (ADCT)?
What is the 5-year average ROE for ADC Therapeutics SA (ADCT)?
How does the current ROE for ADC Therapeutics SA (ADCT) compare to its historical average?